<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PENTAMIDINE ISETIONATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PENTAMIDINE ISETIONATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#handlingAndStorage" data-toggle="tab">Handling and storage</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of <ph outputclass="organism"> <i>Pneumocystis jirovecii</i> </ph> (<ph outputclass="organism"> <i>Pneumocystis carinii</i> </ph> ) pneumonia (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                4 mg/kg once daily for at least 14 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of <ph outputclass="organism"> <i>Pneumocystis jirovecii</i> </ph> (<ph outputclass="organism"> <i>Pneumocystis carinii</i> </ph> ) pneumonia (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg every 4 weeks, alternatively 150 mg every 2 weeks, using suitable equipment&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Visceral leishmaniasis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                3&#8211;4 mg/kg once daily on alternate days, maximum total of 10 injections, course may be repeated if necessary.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cutaneous leishmaniasis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                3&#8211;4 mg/kg 1&#8211;2 times a week until condition resolves.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Trypanosomiasis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                4 mg/kg once daily or on alternate days for a total of 7&#8211;10 injections.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless essential.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce intravenous dose for pneumocystis pneumonia if creatinine clearance less than 10&#8239;mL/minute: in <i>life-threatening infection</i>, use 4&#8239;mg/kg once daily for 7&#8211;10 days, then 4&#8239;mg/kg on alternate days to complete course of at least 14 doses; in <i>less severe infection</i>, use 4&#8239;mg/kg on alternate days for at least 14 doses.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abnormal liver-function tests, acute renal failure, anaemia, arrhythmias (can be severe and sometimes fatal), azotaemia, dizziness, flushing, hyperglycaemia, hyperkalaemia, hypocalcaemia, hypoglycaemia (can be severe and sometimes fatal), hypotension (can be severe and sometimes fatal), leucopenia, nausea, pancreatitis (can be severe and sometimes fatal), rash, Stevens-Johnson syndrome, syncope, taste disturbances, thrombocytopenia, vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> bronchoconstriction (may be prevented by prior use of bronchodilators), cough, shortness of breath, injection site reactions (muscle necrosis, discomfort, pain, induration, abscess formation), injection site reactions (muscle necrosis, discomfort, pain, induration, abscess formation),
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Patient should be lying down when receiving drug parenterally.</p><p>Direct intravenous injection should be avoided whenever possible and <b>never</b> given rapidly; intramuscular injections should be deep and preferably given into the buttock.</p><p>For <i>intravenous infusion</i>, reconstitute 300&#8239;mg with 3&#8211;5&#8239;mL Water for Injections (displacement value may be significant), then dilute required dose with 50&#8211;250&#8239;mL Glucose 5% <i>or</i> Sodium Chloride 0.9%; give over at least 60 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <p>Powder for injection (dissolved in water for injection) may be used for nebulisation.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anaemia
          </li>
          <li>
            bradycardia
          </li>
          <li>
            coronary heart disease
          </li>
          <li>
            history of ventricular arrhythmias
          </li>
          <li>
            hyperglycaemia
          </li>
          <li>
            hypertension
          </li>
          <li>
            hypoglycaemia
          </li>
          <li>
            hypokalaemia
          </li>
          <li>
            hypomagnesaemia
          </li>
          <li>
            hypotension
          </li>
          <li>
            leucopenia
          </li>
          <li>
            risk of severe hypotension following administration
          </li>
          <li>
            thrombocytopenia
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor blood pressure before starting treatment, during administration, and at regular intervals, until treatment concluded.</p><p>Carry out laboratory monitoring according to product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Not licensed for primary prevention of <ph outputclass="organism">
            <i>
            <i>Pneumocystis jirovecii</i>
            </i>
            </ph> (<ph outputclass="organism">
            <i>
            <i>Pneumocystis carinii</i>
            </i>
            </ph>) pneumonia by inhalation of nebulised solution.</p>
            </section>
      </section>



      <section class="tab-pane" id="handlingAndStorage">
        <h2>Advice regarding handling and storage</h2>

            <section class="handlingAndStorage">
              <p>Pentamidine isetionate is toxic and personnel should be adequately protected during handling and administration&#8212;consult product literature.</p>
            </section>
      </section>







      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PENTAMIDINE ISETIONATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76372"><a href="../medicinalForm/PHP76372.html" data-target="#PHP76372" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
